Sofinnova Investments

Sofinnova Investments is a healthcare investment firm committed to funding innovative products that aspire to meaningfully impact the lives of patients.

[Sofinnova Investments @SofinnovaUS]

🗞️Big news from @SofinnovaUS portfolio company Vera Therapeutics.

Positive ORIGIN 3 final efficacy results for TRUTAKNA™ in IgA nephropathy were presented at ASN Kidney Week 2026 and published in the New England Journal of Medicine. #IgAN #KidneyWeek

[Sofinnova Investments @SofinnovaUS]

Five decades. Countless breakthroughs. One remarkable community.

Thank you to everyone who joined us at @SFMOMA to celebrate 50 years of building companies that transform patients' lives. Here's to the next 50.

#Sofinnova50 #Biotech #LifeSciences #Innovation

[Sofinnova Investments @SofinnovaUS]

We’re proud to congratulate @MahaRadhakrish2, Executive Partner at @SofinnovaUS, on being named to @endpts News’ 2026 Women in Biopharma R&D list.

Maha has helped bring 16 medicines to market across her career, including major launches at Bristol Myers Squibb and Biogen. Today at Sofinnova, she brings that operating experience to the next generation of biotech leaders, investing in clinical-stage companies, serving on boards and mentoring founders as they navigate the path from development to patients.

Read the article: https://t.co/isNZrOcSCr

#WomenInBiopharma #Biotech #LifeSciences #VentureCapital #Leadership

[Sofinnova Investments @SofinnovaUS]

In the latest episode of @SofinnovaUS Conversations, we sit down with Adam Rosenthal, PhD, Founder and CEO of @STAR_Biotech, to discuss his entrepreneurial journey, building innovative biotechnology companies, and translating breakthrough science into life-changing medicines for patients.

#SofinnovaConversations #Biotech #Innovation #LifeSciences

[Sofinnova Investments @SofinnovaUS]

@SofinnovaUS Conversations🧬

What can the biology of human aging teach us about developing new medicines?

We sat down with Kristen Fortney, Ph.D., CEO and Co-Founder of @bioagelabs, to discuss how the company is targeting the biology of human aging to develop new medicines for metabolic diseases.

Watch the conversation below. 👇

#SofinnovaConversations #BioAge #Biotech #Longevity

[Sofinnova Investments @SofinnovaUS]

Congrats to our portfolio company @Marea_tx on its combination with @lisata_tx (Nasdaq: $LSTA) and an oversubscribed $225M private placement, which Sofinnova Investments joined alongside leading life sciences investors.

The combined company will advance Marea's next-gen cardioendocrine pipeline MAR001/005 in severe hypertriglyceridemia and MAR002 in acromegaly through key clinical milestones ahead.

@SofinnovaUS General Partner Maha Katabi, PhD, CFA serves on Marea's Board.

👏Congrats to the whole team.

[Marea Therapeutics @Marea_tx]

We're excited to announce that we've entered into a definitive agreement with @Lisata_tx ($LSTA) to combine the companies in an all-stock transaction. The outcome will focus on advancing MAR001/005 and MAR002 through key clinical milestones, including the completion of an ongoing Phase 2b trial in patients with severe hypertriglyceridemia and a Phase 2 trial in patients with acromegaly.

To support the acquisition, we secured an oversubscribed $225 million private placement from a syndicate of leading healthcare investors, which is expected to close concurrently.

Details: https://t.co/vMvfGXYWEC

[Sofinnova Investments @SofinnovaUS]

In a new @PharmaVoice feature examining the next wave of biotech IPOs, @SofinnovaUS Managing Partner @JHealyMD shares his perspective on the importance of building the right foundation.

"Speaking about IPOs generally in July, Dr. Jim Healy, managing partner of Sofinnova Investments, emphasized building an investor base and analyst following that can buoy a company after its debut."

Read the article: https://t.co/3nVg3BEnjA

[Sofinnova Investments @SofinnovaUS]

@SofinnovaUS General Partner, Maha Katabi shares her perspective with @biospace on the steady stream of crossover rounds stock biotech's IPO pipeline.
https://t.co/o37L8bRm4S

[Sofinnova Investments @SofinnovaUS]

At @SofinnovaUS, Merdad will bring deep scientific, clinical and operational expertise to evaluating new investment opportunities and supporting our portfolio companies through development.

We’re excited to have Merdad join the Sofinnova team.

🔗 to read more: https://t.co/b5kC9nO2Xa

[Sofinnova Investments @SofinnovaUS]

Five decades of backing the founders turning bold science into real medicines. This week, @SofinnovaUS rings the @NasdaqExchange Closing Bell in Times Square to celebrate 50 years of funding cures. #Sofinnova50 #Nasdaq

[Nasdaq Exchange @NasdaqExchange]

https://t.co/EtnNCeesPx

[Nasdaq Exchange @NasdaqExchange]

https://t.co/EtnNCeesPx

[Sofinnova Investments @SofinnovaUS]

@SofinnovaUS General Partner Maha Katabi at 2026 Global Conference, “The Next Wave of Health Innovation" panelists highlighted the innovations poised to define the next decade of opportunity across the health ecosystem, and what will be needed to foster them.

“once you treat all of these symptoms, the person becomes a more contributing member of society and their families in general and their communities."

https://t.co/TBM4IDkAZr

#MIGlobal #GlobalConference #Health #Research #Leadership

[Sofinnova Investments @SofinnovaUS]

Our Managing Partner @JHealyMD argues that while mega-mergers may create scale and cost synergies, they don't solve the industry's biggest challenge: innovation.

The next generation of breakthrough medicines will come from companies that partner with, invest in and acquire pioneering biotech - not simply become larger.

Read the full piece here: https://t.co/fdUR9TQPCU

[Sofinnova Investments @SofinnovaUS]

Congratulations to the Expedition Therapeutics team on announcing a $115 million oversubscribed Series B financing and the dosing of the first patient in its Phase 2 COPD clinical trial.

At @SofinnovaUS, we're proud to continue supporting Expedition alongside an top-tier syndicate of new investor as the company advances a potential first-in-class oral DPP1 inhibitor for patients with COPD.

Read the press release:https://t.co/WrXG9H0Kqo

#Biotech #COPD #DrugDevelopment #LifeSciences #Innovation

[Sofinnova Investments @SofinnovaUS]

@SofinnovaUS Executive Partner Jonathan Leff Featured in The Venture Network Top 10 Biotech Investors to Watch: Innovation, Science, Impact 🧬